Secretory breast carcinoma is a rare type of invasive breast cancer named for the way its cells look under the microscope — the cells produce abundant secretions, which gives the tumor a distinctive appearance a pathologist can recognize. It is often slow-growing, and it behaves differently from many other breast cancers with a similar receptor pattern. This guide explains what the name means, how it is found, and how treatment is generally planned.
Key Takeaways
- Secretory breast carcinoma is a rare type of breast cancer, named for the secretions its cells produce, visible under the microscope.
- It often tests negative for hormone receptors and HER2, yet it usually grows slowly and behaves less aggressively than that receptor pattern alone might suggest.
- It has a characteristic gene change that pathologists can test for, which helps confirm the diagnosis.
- It is diagnosed the same way as other breast cancers: imaging, a biopsy, and careful pathology.
- Treatment is generally planned around surgery, with any further treatment shaped by the tumor’s size, lymph nodes, and your overall picture.
- Because it is uncommon, current figures and guidance are published by the American Cancer Society (cancer.org) and the National Cancer Institute (cancer.gov) — ask your team what applies to you.
What the Name Means
Most breast cancer names describe where the cancer started or how the cells are arranged. “Secretory” describes what the cells do: they produce and release secretions, and those secretions collect inside and around the cells in a way that stands out when a pathologist examines the tissue. It is a form of invasive breast cancer, which means the cells have grown beyond the duct where they began into nearby breast tissue.
Secretory carcinoma was first described in younger patients, and it is one of the types that can occasionally occur in adolescents and young adults as well as in older adults. At any age, it is uncommon — it accounts for only a small share of all breast cancers. Our pillar guide, types of breast cancer compared, shows where this rare type sits alongside the more common ones, and our guide to metaplastic breast cancer covers another uncommon type with its own distinctive features.
Because it is rare, many people have never heard of it before their own diagnosis, and information written for breast cancer in general may not describe it well. That can feel isolating, but it also has a practical side: your pathology report carries more weight than any general article, and teams managing rare types often draw on specialist literature and colleagues at larger centers. If reading about the common types leaves you with questions that do not seem to fit your case, that mismatch is expected — bring those questions to your team rather than assuming the general description governs yours.
How This Type Usually Behaves
Two features define how doctors think about secretory carcinoma. The first is its receptor pattern. These tumors usually test negative for the estrogen and progesterone hormone receptors and for HER2 — the pattern often shortened to “triple negative.” For many breast cancers, that pattern points toward faster growth. Secretory carcinoma is an important exception: despite the triple-negative label, it typically grows slowly and tends to be less aggressive than other triple-negative cancers. Our explainer on triple-negative breast cancer describes the broader group and why individual types within it can differ so much.
The second feature is a characteristic gene change found in most of these tumors, created when parts of two genes join together. Pathologists can test for this change, and finding it strongly supports the diagnosis. It does not mean the cancer was inherited — this gene change is found in the tumor cells, not in the body’s other cells, and it is not something you could have caught or passed on like an illness. Like the other rare types described in our guide to adenoid cystic carcinoma of the breast, its outlook depends on the individual details of the tumor, and general descriptions are no substitute for your own pathology report.
| Feature | Secretory carcinoma | More typical triple-negative cancers |
|---|---|---|
| Receptors | Usually negative for ER, PR, and HER2 | Negative for ER, PR, and HER2 by definition |
| Defining feature | Secretions in the cells and a characteristic gene change | Defined by the receptor pattern alone |
| Growth pattern | Often slow-growing and less aggressive | Often faster-growing and more aggressive |
| How common | Rare — a small share of all breast cancers | A broader group covering several types |
The table is a general sketch, not a description of your case: any individual tumor, of any type, is judged on its own full report.
How It Is Found and Confirmed
Secretory carcinoma is usually found the same way as other breast cancers. It may appear as a lump noticed by you or your doctor, or as an area seen on a mammogram or ultrasound. There is no symptom that belongs to this type alone, and it cannot be identified by how a lump feels — the name is only given after tissue is examined.
Confirmation follows the standard path: a biopsy takes a small sample, and a pathologist studies the cells, runs receptor tests, and looks for the features — including, where needed, the characteristic gene change — that separate this type from others that can look similar. Because secretory carcinoma can resemble some benign (non-cancerous) conditions and other cancer types under the microscope, this careful pathology matters. Our guide to understanding your pathology report walks through the terms your report will use, so you can follow along when your team explains the result.
How Treatment Is Generally Planned
Treatment planning for secretory carcinoma follows the same broad approach used for other invasive breast cancers, adjusted to this type’s generally slow-growing nature and to your individual findings. Surgery to remove the tumor is the mainstay for most people. Depending on the tumor’s size and position, that may mean breast-conserving surgery (a lumpectomy) or mastectomy, and the lymph nodes under the arm are usually checked, because node involvement helps shape the rest of the plan.
Whether anything further is recommended — radiation therapy, or medicines such as chemotherapy or other systemic treatments — depends on the size of the tumor, whether lymph nodes are involved, and your overall health and preferences. Because these tumors are often slow-growing and less aggressive, some treatment plans are simpler than the triple-negative label alone might suggest, while larger or node-positive tumors are planned more like other invasive cancers. There is no single standard recipe this article can give you: rare types are exactly where your team’s judgement, and sometimes a second opinion at a center that sees rare cancers, matters most. Individual cases differ, and decisions about your treatment belong with your own doctor and care team.
Questions to Ask Your Doctor
- Did my pathology include the gene-change test that helps confirm secretory carcinoma?
- What were my receptor and HER2 results, and how do they fit with this type’s usual pattern?
- What size is the tumor, and are any lymph nodes involved?
- Which surgery do you recommend for me, and why?
- Do I need any treatment beyond surgery in my case — and what is the reasoning?
- Would it help to have my case reviewed at a center with experience in rare breast cancers?
Frequently Asked Questions
Is secretory breast carcinoma hereditary?
The characteristic gene change is found in the tumor cells themselves, not in the genes you were born with, so this type is not considered an inherited form of breast cancer. If you have a strong family history of cancer, mention it to your team anyway — they can judge whether genetic counselling is relevant for separate reasons.
If it is triple negative, does that mean it is aggressive?
Not necessarily. Secretory carcinoma usually tests triple negative, yet it typically grows slowly and behaves less aggressively than most other triple-negative cancers. This is one reason the exact type matters, not just the receptor results — your team interprets the whole report together.
Can children and teenagers get this type?
It is one of the breast cancer types that can occasionally occur in younger people, including adolescents, though it remains rare at every age. Any breast lump in a young person still deserves prompt medical attention so it can be properly checked.
How is it different from other rare types?
Each rare type has its own cell pattern and behaviour. Secretory carcinoma is defined by its secretions and its characteristic gene change; types such as metaplastic and adenoid cystic carcinoma have different features again. The practical point is that rare types are not interchangeable, and treatment planning leans on the specific diagnosis.
Where can I find reliable figures about this type?
Because this type is uncommon, general statistics are limited and can change as research develops. Current figures are published by the American Cancer Society (cancer.org) and the National Cancer Institute (cancer.gov). Your care team can explain what the available evidence means for your own situation.
Related Articles
- Types of Breast Cancer Compared: A Complete Guide
- Metaplastic Breast Cancer Explained
- Adenoid Cystic Carcinoma of the Breast Explained
- Triple-Negative Breast Cancer Explained
- Understanding Your Breast Cancer Pathology Report
This article is for general educational purposes only and is not medical, legal, or financial advice. It does not replace professional care. Talk to your doctor or care team about your own situation. If you think you may have a medical emergency, call 911.